Contact
Please use this form to send email to PR contact of this press release:
Lipocine Announces the Presentation of Clinical Data for Oral Testosterone Replacement Therapy Product Candidate TLANDO™ (“LPCN 1021”) at the 2016 American Urological Association Annual Meeting
TO: